Background: Whole body and abdominal obesity are associated with increased risk of diabetes mellitus and heart disease. The effects of testosterone therapy on whole body and visceral fat mass in HIVinfected men with abdominal obesity are unknown.
Results: Baseline characteristics were balanced between groups. In 75 subjects evaluated, median percent change from baseline to wk 24 in visceral fat did not differ significantly between groups (testosterone 0.3%, placebo 3.1%, P ϭ 0.75). Total (testosterone Ϫ1.5%, placebo 4.3%, P ϭ 0.04) and sc (testosterone Ϫ7.2%, placebo 8.1%, P Ͻ 0.001) abdominal fat mass decreased in testosterone-treated men, but increased in placebo group. Testosterone therapy was associated with significant decrease in whole body, trunk, and appendicular fat mass by dual energy x-ray absorptiometry (all P Ͻ 0.001), whereas whole body and trunk fat increased significantly in the placebo group. The percent of individuals reporting a decrease in abdomen (P ϭ 0.01), neck (P ϭ 0.08), and breast size (P ϭ 0.01) at wk 24 was significantly greater in testosterone-treated than placebo-treated men. Testosterone-treated men had greater increase in lean body mass than placebo (testosterone 1.3%, placebo Ϫ0.3, P ϭ 0.02). Plasma insulin, fasting glucose, and total high-density lipoprotein and low-density lipoprotein cholesterol levels did not change significantly. Testosterone therapy was well tolerated.
Conclusions:
Testosterone therapy in HIV-positive men with abdominal obesity and low testosterone was associated with greater decrease in whole body, total, and sc abdominal fat mass and a greater increase in lean mass compared to placebo. However, changes in visceral fat mass were not significantly different between groups. Further studies are needed to determine testosterone effects on insulin sensitivity and cardiovascular risk. T HE ACCUMULATION OF visceral fat is strongly associated with increased risk for cardiovascular disease and type 2 diabetes mellitus (1) (2) (3) (4) (5) (6) (7) (8) . Even among individuals with nearly normal weight, those with abdominal obesity have a higher risk of diabetes, atherogenic dyslipidemia, hypertension, coronary artery disease, and in women, breast cancer (6) . Abdominal adiposity is an important component of the metabolic syndrome (8 -10) , a condition associated with increased risk of atherosclerotic heart disease. The waist-to-hip ratio, a measure of abdominal adiposity, is a better predictor of coronary artery disease than other measures of obesity such as body mass index.
Although population-based studies of the prevalence of abdominal obesity in HIV-infected men and women have been scarce, there is agreement that many HIV-infected subjects on antiretroviral therapy experience an increase in abdominal girth (11) (12) (13) (14) (15) . Widely varying estimates of abdominal adiposity in HIV-infected individuals have been published, reflecting the lack of agreed upon case definitions, and differences in methods for assessing fat distribution (13) (14) (15) (16) (17) . However, there is agreement that fat redistribution syndromes are being observed with increasing frequency, and there is concern about the long-term cardiovascular impact of abdominal obesity (15, 17) . Fat distribution syndromes stigmatize the subject and affect an individual's selfimage and adherence to antiretroviral therapy.
The mechanisms of visceral fat accumulation in HIV-infected subjects are not known, but are undoubtedly multifactorial. Androgen deficiency, increased glucocorticoid sensitivity and cytokine burden, and decreased activity of the retinoid X receptor-peroxisome proliferator-activated receptor ␥ regulatory complex and other unknown mechanisms collectively favor accumulation of visceral fat (12) . This study focused only on correcting low testosterone levels in a subset of HIV-infected men with abdominal obesity.
Testosterone is a major determinant of regional fat metabolism (18 -20) and body composition (19 -22) . Testosterone inhibits uptake of triglycerides and enhances lipid mobilization from the visceral fat (23) . Testosterone levels are associated inversely with visceral fat mass (24 -29) . Testosterone therapy has been reported to decrease visceral fat, glucose, and insulin levels in middle-aged men with abdominal obesity (19, 20) and type 2 diabetes (30) . Although no randomized trials of testosterone therapy in HIV-associated abdominal obesity have been conducted, there is considerable off-label use of testosterone in HIV-infected men. Therefore, we evaluated the efficacy of testosterone therapy in HIV-infected men with abdominal obesity and low or lownormal testosterone levels. We defined abdominal obesity as a waist-to-hip ratio greater than 0.95 or an abdominal circumference greater than 100 cm, because values above these thresholds in men have been associated with increased risk of cardiovascular disease and type 2 diabetes (6, 10).
Subjects and Methods
The study protocol, AIDS Clinical Trials Group (ACTG) 5079, was approved by institutional review boards for human subjects at all ACTG participating sites. All participants provided written informed consent.
Study design
This was a multisite, placebo-controlled, randomized, parallel group trial in which eligible subjects were randomly assigned in a 1:1 ratio to receive either testosterone or placebo gel daily for a 24-wk, double-blind period. At the end of the double-blind period, subjects were given the option of continuing open-label testosterone therapy for additional 24 wk. We report efficacy results for the blinded phase, but include safety data from the entire study.
Subjects
The eligible participants were HIV-infected men, 18 -70 yr of age with abdominal obesity, defined as waist-to-hip ratio greater than 0.95 or mid-waist circumference greater than 100 cm, and serum total testosterone between 125-400 ng/dl. Because HIV-infected men have higher SHBG concentrations than healthy men (31), measurement of total testosterone alone may underestimate the degree of androgen deficiency. Therefore, we also included men who had free testosterone less than 50 pg/ml by equilibrium dialysis or bioavailable testosterone less than 115 ng/dl by ammonium sulfate precipitation method. The participants were required to have been on stable potent antiretroviral regimens for at least 3 months, planning to remain on this regimen and not to change diet and exercise behavior for at least 24 wk after randomization, and have plasma HIV RNA less than 10,000 copies per milliliter. HIV infection was documented by any licensed ELISA test kit and confirmed by a second method. Men with prostate or breast cancer, benign prostatic hypertrophy with American Urological Association symptom score greater than 7, prostate-specific antigen (PSA) equal to or greater than 4 ng/ml, diabetes mellitus, hemoglobin less than or equal to 91 g/liter or greater than the upper limit of normal (ULN), aspartate aminotransferase or alanine aminotransferase more than five times ULN, or creatinine two or more times ULN were excluded. We also excluded those who had received any androgen, recombinant human GH, appetite stimulant, or glucocorticoids within 12 wk of study entry. Opportunistic infection within 12 wk, active malignancy, decompensated congestive heart failure, and untreated severe sleep apnea were additional causes for exclusion.
Randomization, stratification, and blinding
Randomization was stratified by RNA copy number (detectable or undetectable, defined as HIV RNA copy number Ͻ 200 copies/ml by Roche Amplicor HIV-1 Monitor UltraSensitive assay) with approximate balance within each site. Investigators, subjects, and staff were unaware of treatment assignment during the double-blind phase.
Treatment
During the double-blind phase, participants received either 10 g transdermal testosterone gel (AndroGel; Solvay Pharmaceuticals, Marietta, GA) or matching placebo gel. Testosterone gel is a clear, hydroalcoholic gel that contains 1% testosterone, ethanol, purified water, sodium hydroxide, carbomer 940, and isopropyl myristate that provides a continuous transdermal delivery of testosterone for 24 h. A daily application of 10 g of gel delivers 100 mg testosterone to the surface of the skin. Approximately 10% of applied testosterone is absorbed across the skin during the 24-h period, providing a nominal daily delivery of 10 mg testosterone. This dose was selected because in pivotal trials it raised testosterone levels in androgen-deficient men into the mid-normal range (32) . Subjects were advised to apply the gel daily on the abdominal skin, wash their hands after application, and keep the area covered with clothing to minimize the risk of transfer.
Outcome measures
At baseline, evidence for HIV-infection was documented, and medical evaluation and blood counts and chemistries were performed to confirm conformity with eligibility criteria. Single-slice abdominal computerized tomography (CT) and body composition analysis by dual energy x-ray absorptiometry (DEXA) were performed at baseline and during wk 12 and 24. Anthropometric and quality of life measurements were made at entry and during wk 12 and 24. Perceptions of weight change and body composition changes assessed by questionnaires, and the American Urological Association prostate symptom score, PSA, and digital prostate examinations were performed at baseline and during wk 12 and 24. Blood counts and chemistries were obtained every 6 wk. Serum total and free testosterone levels, LH, estradiol, and SHBG levels were measured at baseline and during wk 24.
Statistical considerations
Sample size. The sample size was based on the percent change in visceral fat cross-sectional area, the primary outcome during the blinded phase. A priori, we determined that a sample size of 86 subjects would provide 80% power to detect an 18.1% decrease in visceral fat area, with sd of 30.4 as previously reported in HIV-seronegative men with abdominal obesity (33), using a significance level of 0.10 (two-sided). This allowed for 20% of subjects not to be unable to be evaluated. An 18% decrease in visceral fat mass was deemed clinically important as in a previous study of recombinant human GH; this change was associated with the perceptions of the patient of change in abdominal girth (33) .
Data analysis.
We used an intention-to-treat strategy with last value carried forward for the blinded phase. Thus, we used wk 12 data if wk 24 data were unavailable for a measurement. If baseline data were unavailable, or if there was no follow-up data available for either wk 12 and 24, the participant was considered unable to be evaluated. Missing data were treated as missing completely at random.
For continuous variables, comparisons between groups used a Wilcoxon rank sum test because there was evidence that the overall data were not consistent with normality. For continuous variables, the significance of changes over time within a treatment group was tested using a Wilcoxon signed rank test. Fisher's exact test was used for categorical data. For paired binary data (e.g. HIV viral loads above or below the lower limit of detection over time), exact McNemar's test was used to assess changes over time. The Mantel-Haenszel test for trend was used to compare ordered categorical data between groups for participant self-perceptions. The log rank test was used to compare time to dropout and time to drug discontinuation between groups. Spearman rank correlation was used to assess the relationship between continuous variables. As specified in the protocol, results are considered statistically significant if P Ͻ 0.10 (two-sided).
Hormone measurements
Hormone levels were measured by Quest Diagnostics-Nichols Institute laboratory (San Juan Capistrano, CA). Screening testosterone level was measured by an automated chemiluminescent assay; at the completion of the study, total testosterone levels in all samples were assayed, using liquid chromatography, tandem mass spectrometry. Free testosterone level was measured by an equilibrium dialysis method. Intraassay and interassay CVs were as follows: total testosterone 7.1 and 9.8%; free testosterone 11.8 and 11.6%. Serum estradiol was measured by the ADVIA Centaur immunoassay system (Bayer HealthCare, Tarrytown, NY), a competitive chemiluminescent immunoassay in which estradiol in the sample competes with acridinium ester-labeled estradiol for rabbit anti-estradiol antibody. LH was measured by a two-site chemiluminescent immunoassay (ADVIA Centaur system; Bayer HealthCare). SHBG was assayed using the IMMULITE 2000 immunoassay (Diagnostic Products Corp., Los Angeles, CA), which uses a solid-phase, two-site chemiluminescent immunometric assay.
Measurement of abdominal fat by CT scanning
Transverse CT scans of abdomen (L4 -L5) were performed using a standardized protocol; this measure of abdominal fat correlates highly with multiple scans through the abdomen (34) . All scans were read centrally at Tufts University using a standardized protocol using Slice-o-Matic software (Tomovision, Montreal, Canada). The display field was used to scale the image pixels for analysis and demarcate regions of interest.
Body composition analysis by DEXA
Whole body and regional body composition were evaluated by DEXA scanning. The scanners were calibrated by using a soft tissue phantom. At each site, the same scanner was used for all evaluations on individual subjects. Regional body composition analysis was performed centrally at Tufts University using a standardized protocol. The extremities and trunk regions were demarcated manually, and appendicular lean and fat masses were calculated by adding the lean and fat mass of the arms and legs.
Results

Flow of subjects
Eighty eight subjects were randomized between July 2001 and July 2004 at 19 sites, divided equally between treatment arms; 80 subjects completed the double-blind phase and 75 completed all phases of the study (Fig. 1 ). There were eight dropouts during the double-blind phase: five in the testoster- one group (one subject relocated, one incarcerated, one unable to come, one noncompliant with medications, and one refused contact) and three in the placebo group (one started using prescription testosterone, one started using prescription medication that was not allowed, and one withdrew consent). There were 12 premature drug discontinuations before wk 24: eight in the testosterone group (including one inadvertently starting open-label treatment) and four in the placebo group.
Baseline characteristics
The two groups did not differ in terms of age, body mass index, visceral fat mass, testosterone levels, CD4
ϩ T lymphocyte counts, or HIV copy number ( Table 1 ). The median age was 47 yr; 72% of participants were Caucasian, and 11% previously used iv drugs.
CT adipose tissue mass
By intention to treat analysis, neither median changes in visceral fat area from baseline to wk 24 in testosterone (0.3%) and placebo (3.1%) groups (both P Ͼ 0.80), nor the difference between groups was statistically significant (90% confidence interval of difference between groups Ϫ12.8%, 11.2%, P ϭ 0.75) (Fig. 2) . Per protocol analysis of subjects who completed both baseline and wk-24 CT scans revealed similar results (median change, 0.9 and 3.2% in testosterone and placebo groups, respectively; P ϭ 0.83).
Although changes in visceral fat area within groups were not statistically significant, total abdominal fat by CT decreased from baseline to wk 24 in testosterone-treated men (Ϫ1.5%) and increased in placebo-treated men (4.3%); this difference was significantly different between groups (P ϭ 0.03).
Subcutaneous abdominal fat decreased significantly from baseline to wk 24 in testosterone group (Ϫ7.2%, P Ͻ 0.001), but increased in placebo group (8.1%, P ϭ 0.03); between-group difference for change in sc fat was significant (P Ͻ 0.001).
Qualitatively similar results were found for betweengroup comparisons for changes from baseline to wk 12 in visceral, total abdominal, and abdominal sc fat (not shown).
Body composition analyses by DEXA
Whole body fat mass decreased significantly from baseline in testosterone-treated group (Ϫ1.6 kg, Ϫ7.9%), and increased in placebo-treated group (ϩ0.7 kg, ϩ4.5%); the change from baseline to wk 24 was significantly different between the two groups (P Ͻ 0.001) (Fig. 2) . Trunk fat measured by DEXA also decreased in testosterone-treated men (Ϫ1.2 kg, Ϫ9.9%), and increased in placebo-treated men from baseline to wk 24 (0.3 kg, ϩ4.6%); the change in trunk fat was significantly different between the two groups (P Ͻ 0.001). Similarly, extremity fat decreased from baseline to wk 24 to a significantly greater extent in testosterone-treated men (Ϫ0.5 kg, Ϫ10.1%) than in placebo-treated men (ϩ0.2 kg, ϩ3.1%) (P Ͻ 0.001 for betweengroup difference).
Lean body mass
There were significant differences in change from baseline to wk 24 in whole body lean mass between groups (P ϭ 0.02), with an increase in lean body mass in the active treatment group (1.3 kg) and a decrease (Ϫ0.3 kg) in the placebo group. The changes from baseline to wk 24 in trunk (P ϭ 0.02) and extremity (P ϭ 0.01) lean mass were significantly greater in testosterone-treated men than in placebo-treated men.
Anthropometrics and body weight
Waist circumference and waist-to-hip ratio decreased from baseline to wk 24 in testosterone-treated men (Fig. 3) ; the changes in waist circumference and waist-to-hip ratio were significantly greater in the testosterone group than placebo group (P ϭ 0.03 for both).
Body weight and body mass index decreased significantly from baseline to wk 24 in the testosterone group (P Ͻ 0.10 for both), but between-group differences in change in either measure were not significant (both P Ͼ 0.20).
Perception of body composition change and overall health
In comparison to placebo, a significantly greater percent of individuals in the testosterone group reported a decrease in the abdomen (P ϭ 0.01), neck (P ϭ 0.08), and breast size (P ϭ 0.01) at wk 24. The two groups did not differ significantly in overall health perceptions at wk 24.
Hormone levels
As expected, the increments in nadir total and free testosterone levels from baseline to wk 24 were significantly greater in testosterone group than placebo (P ϭ 0.07 for total testosterone, and 0.01 for free testosterone; Fig. 4 ). Serum LH levels decreased significantly in the testosterone group from baseline to wk 24 (P Ͻ 0.001); the change from baseline to wk 24 was greater in the testosterone group than the placebo group (P Ͻ 0.001). Serum SHBG levels did not change significantly in either group. Serum estradiol levels increased in the testosterone group, but the differences in the change from baseline were not significantly different between groups.
Plasma lipids and insulin levels
The changes from baseline in plasma glucose and insulin levels, and homeostatic model assessment (HOMA) and quantitative insulin sensitivity check (QUICKI) indices of insulin sensitivity did not differ significantly between groups (Table 2) . Plasma total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, non-HDL cholesterol, and triglyceride levels did not change significantly from baseline in either group (Table 2) .
Safety analysis
The increase in PSA from baseline to wk 24 was greater in the testosterone (0.1 ng/ml) than placebo group (0 ng/ml; P ϭ 0.06). PSA level in two men in the placebo group and in one man in the testosterone group exceeded 4 ng/ml or had an increase of more than 1 ng/ml during the blinded phase. During the open-label phase, two additional men originally assigned to placebo group had PSA level above 4 ng/ml or had an increase of more than 1 ng/ml.
Hematocrit increased significantly in both groups; the change in hematocrit from baseline to wk 24 was not sig- nificantly different between groups. During the blinded phase, three testosterone-treated men developed hematocrit values above 54%. Hematocrit rose above 54% in three men during the open-label phase, one originally assigned to the testosterone group and two in the placebo group.
There were no significant differences between groups for changes from baseline to wk 24 in CD4 ϩ or CD8 ϩ T lymphocyte counts, HIV RNA copy number, aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase. During the blinded phase, there was one grade 4 elevation in creatine phosphokinase in the testosterone group and one grade 4 elevation in fasting glucose in the placebo group. During the open-label phase, there was one grade 4 event (backache) in the placebo group; one person in the testosterone group developed grade 4 triglyceride level.
Relationship of testosterone levels with fat measures
Although total testosterone levels were correlated significantly inversely with visceral fat area at baseline and at wk 24, there was no significant correlation between baseline testosterone levels and changes in visceral or sc fat mass (the greatest magnitude of correlation was Ϫ0.20, P ϭ 0.23). Also, there was no significant correlation between change in testosterone levels and changes in visceral or sc fat mass.
Discussion
In comparison to placebo, testosterone therapy of HIVinfected men with abdominal obesity was not associated with a significantly greater reduction in visceral fat mass. However, total body, trunk, abdominal sc, and appendicular fat mass decreased to a greater extent in testosterone group than in the placebo group. These changes in abdominal fat mass in the testosterone-treated men were associated with greater reductions in waist circumference and waist-to-hip ratio and in perceptions of change in abdomen size than those observed in the placebo group. Testosterone administration was also associated with a greater accretion of lean body mass than placebo. The treatment was associated with a low frequency of adverse events. Thus, testosterone therapy was more effective than placebo in inducing a reduction in whole body and abdominal fat, although it did not significantly reduce visceral fat mass.
There was concordance among various measures of fat distribution and between objective and self-reported measures of fat distribution. Thus, whole body and trunk fat mass assessed by using DEXA decreased with testosterone administration. Similarly, CT assessment demonstrated a significant reduction in total abdominal and abdominal sc fat during testosterone administration. These changes in CT and DEXA measures of abdominal fat during testosterone administration were associated with decreases in waist circumference and waist-to-hip ratio. Importantly, changes in abdominal fat, assessed objectively, were accompanied by the perception of the subject of decreased abdomen size.
Testosterone treatment was associated with low frequency of adverse effects, in line with that reported in testosterone trials in non-HIV-infected men (35) (36) (37) and HIV-infected men (38 -41) . The skin tolerability of the testosterone gel was excellent. The frequency of increases in hematocrit and PSA in testosterone-treated men were similar to those reported in testosterone trials in androgen-deficient men (35, 37, 42) . Plasma lipids, including HDL cholesterol, CD4 ϩ and CD8 ϩ T lymphocyte counts, and HIV RNA copy number did not change significantly during testosterone administration. The study was not powered to determine the effects of testosterone administration on prostate or cardiovascular event rates. Furthermore, the short treatment duration does not permit meaningful inferences about long-term safety of testosterone administration. Our data differ from those of Marin et al. (19, 20) who had reported that testosterone supplementation of seronegative middle-aged men with truncal obesity decreased visceral fat volume and glucose concentration and improved insulin sensitivity. In epidemiological studies, serum testosterone levels are correlated inversely with fat mass (25, 26, 43) . Testosterone replacement of young and older hypogonadal men (36, 37, 44, 45) is associated with reduction in overall fat mass. Although there is considerable evidence that testosterone administration decreases whole body fat mass (37, 45), we do not know whether testosterone therapy can reduce visceral fat mass. In our study, whole body fat mass and trunk fat decreased during testosterone administration, but the changes in visceral fat mass were not significant. In a previous study in healthy, young men, graded doses of testosterone enanthate in GnRH-agonist-treated men were associated with dose-dependent reduction in abdominal sc and visceral fat (46) . However, significant reductions in visceral fat were observed only at supraphysiological doses of testosterone enanthate (46) . In this trial, the increments in total and free testosterone level with therapy were small, reflecting the nadir levels measured 24 h after gel administration. Smaller-than-expected increments in testosterone levels during treatment could also be the result of alterations in metabolic clearance of testosterone induced by anti-retroviral drugs and other chemotherapeutic agents used in HIV-infected men (47, 48) . Some of our participants had baseline testosterone levels in the low-normal range and did not meet the definition of androgen deficiency proposed by the Endocrine Society Expert Panel (37) . It is possible that testosterone, when administered in doses that increase serum testosterone levels to a higher level than those achieved in this study, might reduce visceral fat mass in HIV-infected men whose testosterone levels are clearly in the hypogonadal range.
We do not know what magnitude of change in abdominal or whole body fat is clinically significant. Whole body fat mass decreased by about 8% in testosterone-treated men and increased by almost 5% in placebo-treated men. Similarly, the reduction in trunk fat was about 10% in testosteronetreated men. This loss of abdominal fat mass was perceived by subjects as a reduction in abdomen size, although we do not know whether this decrease in abdominal fat mass without a significant change in visceral fat mass reduces the risk of diabetes and cardiovascular disease. In epidemiological studies, trunk fat (49) and abdominal sc fat (50) have been associated with insulin resistance. A decrease in whole body fat mass has been associated with decreased risk of diabetes mellitus (51); however, we do not know whether a decrease in peripheral sc fat mass has a beneficial effect on insulin sensitivity, and the risk of diabetes mellitus and heart disease. In patients with lipoatrophy, further loss of peripheral sc fat may possibly be deleterious.
This study was limited to men because testosterone administration in the doses that were used in this study would induce virilization in women. The effects of testosterone administration in women might be different from those in men (52, 53) . Unlike men, serum testosterone levels are associated with insulin resistance and increased cardiovascular risk in women (43, (52) (53) (54) . Therefore, these data should not be extrapolated to women.
This initial study in HIV-infected men with visceral obesity was not designed to determine the effects of testosterone therapy on cardiovascular event rates; those trials would require a much larger sample size and a longer treatment duration than this study. We do not know whether increases in lean body mass and decreases in whole body fat mass would translate into improvements in insulin sensitivity, which was not assessed rigorously. Also, these data are not applicable to HIV-infected patients with lipoatrophy. Although testosterone therapy decreased whole body, abdominal, and appendicular fat mass, it did not significantly reduce visceral fat mass. Therefore, our data do not justify the widespread off-label use of testosterone in HIV-infected men with fat redistribution syndromes. Further studies are needed to determine the effects of testosterone therapy on insulin sensitivity and cardiovascular outcomes.
